{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06064162",
            "orgStudyIdInfo": {
                "id": "REDI2022MS"
            },
            "organization": {
                "fullName": "Alta Bates Summit Medical Center",
                "class": "OTHER"
            },
            "briefTitle": "Ketamine for MS Fatigue",
            "officialTitle": "A Pilot Study of Intravenous, Subanesthetic Dose of Ketamine Versus Placebo, A Crossover Design, for Multiple Sclerosis Related Fatigue",
            "therapeuticArea": [
                "Other"
            ],
            "study": "ketamine-for-ms-fatigue"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-12-05",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-09-26",
            "studyFirstSubmitQcDate": "2023-09-26",
            "studyFirstPostDateStruct": {
                "date": "2023-10-03",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-05",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-06",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Alta Bates Summit Medical Center",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to see whether using ketamine to increase glutamate in the prefrontal cortex can reduce Multiple Sclerosis (MS) related fatigue. The investigator proposes a prospective, crossover, randomized, placebo-controlled study to assess the efficacy and safety of low, single dose Ketamine, to assess its efficacy and safety in patients with MS-related fatigue.",
            "detailedDescription": "The study treatment is designed in two 28-day cycles: for each cycle, participants will receive study infusion on Day 1 and complete follow-up visits during Days 7 and 28. Participants are randomized 1:1 to receive either ketamine (active treatment) or saline solution (placebo treatment) for their first infusion. They will not be blinded to their study assignment: the study doctor will disclose their assigned treatment group.\n\nAfter their first infusion cycle, participents will crossover to the other treatment group. Worded differently, if a participant received ketamine during their first infusion, they will receive placebo treatment during their second infusion. Conversely, if a participant received saline treatment during their first infusion, they will receive ketamine during their second infusion."
        },
        "conditionsModule": {
            "conditions": [
                "Multiple Sclerosis"
            ],
            "keywords": [
                "MS related Fatigue"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "EARLY_PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "CROSSOVER",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 20,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Ketamine (active treatment)",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "dose of 0.5 mg/kg intravenously over 40 minutes on day 1",
                    "interventionNames": [
                        "Drug: ketamine"
                    ]
                },
                {
                    "label": "Saline (placebo treatment)",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Placebo (saline solution) over 40 minutes on day 1",
                    "interventionNames": [
                        "Drug: ketamine"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "ketamine",
                    "description": "60mg (.5mg/kg over 40 minutes intravenously)",
                    "armGroupLabels": [
                        "Ketamine (active treatment)",
                        "Saline (placebo treatment)"
                    ],
                    "otherNames": [
                        "Ketalar"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Improve Fatigue Scores",
                    "description": "a statistically significant change in the level of fatigue score as measured by the Multiple Schlerosis fatigue scales: Modified Fatigue Impact Scale (MFIS) between baseline and day 28 post study drug infusion. Rating scale is 0 to 4 with 0 being \"never\" and 4 being \"almost always.\"",
                    "timeFrame": "28 days post study drug infusion"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Improve Quality of Life",
                    "description": "A statistically significant change in the patient's quality of life as measured by Functional Index for Living with Multiple Sclerosis (FILMS) between baseline and day 28. Score is rated 1 to 5 with 1 being \"bad\" and 5 being \"good.\"",
                    "timeFrame": "Between baseline and day 28"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Female and Male patients with any form of CDMS ages 18-65 inclusive\n2. Report fatigue which is interfering with QOL\n3. Able and willing to sign informed consent\n4. Stable on DMT for at least 3 months prior to baseline visit\n5. Not experiencing an MS relapse within 90 days prior to baseline visit.\n6. Must agree to practice an acceptable method of contraception\n7. Experiencing significant fatigue due to MS (MFIS of \u226510)\n\nExclusion Criteria:\n\n1. Allergy to Ketamine\n2. Taking medications which may interact with ketamine\n3. Change in DMT within 3 months prior to baseline visit\n4. MS relapse within 90 days of the baseline visit\n5. Confirmed diagnosis of untreated Sleep Apnea\n6. Confirmed diagnosis of periodic limb movement disorder\n7. Serious infection in the 30 days prior to baseline visit.\n8. Patients with significant comorbid conditions:\n\n   1. Untreated hypertension (SBP\\>160, DBP\\>100 at baseline)\n   2. Liver disease\n   3. Significant renal disease\n   4. History of cardiac arrhythmia\n   5. Any comorbidities which at the opinion of the investigators post undue risk\n9. Current alcohol or drug abuse\n10. Participation in another interventional clinical trial in the past 3 months.\n11. Pregnant or lactating\n12. Any condition which in the opinion of the investigators will cause safety concerns for the patient, or inability to comply with the protocol.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "65 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Deepak Soneji, MD",
                    "role": "CONTACT",
                    "phone": "510.204.8140",
                    "email": "Deepak.Soneji@sutterhealth.org"
                },
                {
                    "name": "Joanna Cooper, MD",
                    "role": "CONTACT",
                    "phone": "510.204.8140",
                    "email": "Joanna.Cooper@sutterhealth.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Deepak Soneji, MD",
                    "affiliation": "Sutter East Bay Medical Foundation",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Alta Bates Summit Medical Center",
                    "status": "RECRUITING",
                    "city": "Berkeley",
                    "state": "California",
                    "zip": "94705",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Janet Han, RN",
                            "role": "CONTACT",
                            "phone": "510-204-1757",
                            "email": "Janet.Han@sutterhealth.org"
                        },
                        {
                            "name": "Lilly Murray, RN",
                            "role": "CONTACT",
                            "phone": "510-204-1608",
                            "email": "Lilly.Murray@sutterhealth.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.87159,
                        "lon": -122.27275
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "32633662",
                    "type": "RESULT",
                    "citation": "Fitzgerald KC, Morris B, Soroosh A, Balshi A, Maher D, Kaplin A, Nourbakhsh B. Pilot randomized active-placebo-controlled trial of low-dose ketamine for the treatment of multiple sclerosis-related fatigue. Mult Scler. 2021 May;27(6):942-953. doi: 10.1177/1352458520936226. Epub 2020 Jul 7."
                },
                {
                    "pmid": "30312839",
                    "type": "RESULT",
                    "citation": "Saligan LN, Farmer C, Ballard ED, Kadriu B, Zarate CA Jr. Disentangling the association of depression on the anti-fatigue effects of ketamine. J Affect Disord. 2019 Feb 1;244:42-45. doi: 10.1016/j.jad.2018.10.089. Epub 2018 Oct 6."
                },
                {
                    "pmid": "22935407",
                    "type": "RESULT",
                    "citation": "Induruwa I, Constantinescu CS, Gran B. Fatigue in multiple sclerosis - a brief review. J Neurol Sci. 2012 Dec 15;323(1-2):9-15. doi: 10.1016/j.jns.2012.08.007. Epub 2012 Aug 27."
                },
                {
                    "pmid": "17409388",
                    "type": "RESULT",
                    "citation": "Kos D, Kerckhofs E, Nagels G, D'hooghe MB, Ilsbroukx S. Origin of fatigue in multiple sclerosis: review of the literature. Neurorehabil Neural Repair. 2008 Jan-Feb;22(1):91-100. doi: 10.1177/1545968306298934. Epub 2007 Apr 4."
                },
                {
                    "pmid": "15824337",
                    "type": "RESULT",
                    "citation": "Stankoff B, Waubant E, Confavreux C, Edan G, Debouverie M, Rumbach L, Moreau T, Pelletier J, Lubetzki C, Clanet M; French Modafinil Study Group. Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology. 2005 Apr 12;64(7):1139-43. doi: 10.1212/01.WNL.0000158272.27070.6A."
                },
                {
                    "pmid": "24963407",
                    "type": "RESULT",
                    "citation": "Asano M, Finlayson ML. Meta-analysis of three different types of fatigue management interventions for people with multiple sclerosis: exercise, education, and medication. Mult Scler Int. 2014;2014:798285. doi: 10.1155/2014/798285. Epub 2014 May 14."
                },
                {
                    "pmid": "33242419",
                    "type": "RESULT",
                    "citation": "Nourbakhsh B, Revirajan N, Morris B, Cordano C, Creasman J, Manguinao M, Krysko K, Rutatangwa A, Auvray C, Aljarallah S, Jin C, Mowry E, McCulloch C, Waubant E. Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial. Lancet Neurol. 2021 Jan;20(1):38-48. doi: 10.1016/S1474-4422(20)30354-9. Epub 2020 Nov 23."
                },
                {
                    "pmid": "29464379",
                    "type": "RESULT",
                    "citation": "Broicher SD, Filli L, Geisseler O, Germann N, Zorner B, Brugger P, Linnebank M. Positive effects of fampridine on cognition, fatigue and depression in patients with multiple sclerosis over 2 years. J Neurol. 2018 May;265(5):1016-1025. doi: 10.1007/s00415-018-8796-9. Epub 2018 Feb 20."
                },
                {
                    "pmid": "31741743",
                    "type": "RESULT",
                    "citation": "Meca-Lallana V, Branas-Pampillon M, Higueras Y, Candeliere-Merlicco A, Aladro-Benito Y, Rodriguez-De la Fuente O, Salas-Alonso E, Maurino J, Ballesteros J. Assessing fatigue in multiple sclerosis: Psychometric properties of the five-item Modified Fatigue Impact Scale (MFIS-5). Mult Scler J Exp Transl Clin. 2019 Nov 9;5(4):2055217319887987. doi: 10.1177/2055217319887987. eCollection 2019 Oct-Dec."
                },
                {
                    "pmid": "19737850",
                    "type": "RESULT",
                    "citation": "Wesson JM, Cooper JA, Jehle LS, Lockhart SN, Draney K, Barber J. The functional index for living with multiple sclerosis: development and validation of a new quality of life questionnaire. Mult Scler. 2009 Oct;15(10):1239-49. doi: 10.1177/1352458509107019. Epub 2009 Sep 8."
                },
                {
                    "pmid": "26774513",
                    "type": "RESULT",
                    "citation": "Beard C, Hsu KJ, Rifkin LS, Busch AB, Bjorgvinsson T. Validation of the PHQ-9 in a psychiatric sample. J Affect Disord. 2016 Mar 15;193:267-73. doi: 10.1016/j.jad.2015.12.075. Epub 2015 Dec 31."
                }
            ],
            "seeAlsoLinks": [
                {
                    "label": "National Multiple Sclerosis Society",
                    "url": "https://www.nationalmssociety.org/"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009103",
                    "term": "Multiple Sclerosis"
                },
                {
                    "id": "D000012598",
                    "term": "Sclerosis"
                },
                {
                    "id": "D000005221",
                    "term": "Fatigue"
                }
            ],
            "ancestors": [
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                },
                {
                    "id": "D000020278",
                    "term": "Demyelinating Autoimmune Diseases, CNS"
                },
                {
                    "id": "D000020274",
                    "term": "Autoimmune Diseases of the Nervous System"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                },
                {
                    "id": "D000003711",
                    "term": "Demyelinating Diseases"
                },
                {
                    "id": "D000001327",
                    "term": "Autoimmune Diseases"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12060",
                    "name": "Multiple Sclerosis",
                    "asFound": "Multiple Sclerosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M15415",
                    "name": "Sclerosis",
                    "asFound": "Sclerosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8364",
                    "name": "Fatigue",
                    "asFound": "Fatigue",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4629",
                    "name": "Autoimmune Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M22098",
                    "name": "Demyelinating Autoimmune Diseases, CNS",
                    "relevance": "LOW"
                },
                {
                    "id": "M22094",
                    "name": "Autoimmune Diseases of the Nervous System",
                    "relevance": "LOW"
                },
                {
                    "id": "M6909",
                    "name": "Demyelinating Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000007649",
                    "term": "Ketamine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000700",
                    "term": "Analgesics"
                },
                {
                    "id": "D000018689",
                    "term": "Sensory System Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000000778",
                    "term": "Anesthetics, Dissociative"
                },
                {
                    "id": "D000018686",
                    "term": "Anesthetics, Intravenous"
                },
                {
                    "id": "D000018681",
                    "term": "Anesthetics, General"
                },
                {
                    "id": "D000000777",
                    "term": "Anesthetics"
                },
                {
                    "id": "D000002492",
                    "term": "Central Nervous System Depressants"
                },
                {
                    "id": "D000018691",
                    "term": "Excitatory Amino Acid Antagonists"
                },
                {
                    "id": "D000018683",
                    "term": "Excitatory Amino Acid Agents"
                },
                {
                    "id": "D000018377",
                    "term": "Neurotransmitter Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10674",
                    "name": "Ketamine",
                    "asFound": "Nerve",
                    "relevance": "HIGH"
                },
                {
                    "id": "M21860",
                    "name": "Pharmaceutical Solutions",
                    "relevance": "LOW"
                },
                {
                    "id": "M4032",
                    "name": "Analgesics",
                    "relevance": "LOW"
                },
                {
                    "id": "M4107",
                    "name": "Anesthetics",
                    "relevance": "LOW"
                },
                {
                    "id": "M4108",
                    "name": "Anesthetics, Dissociative",
                    "relevance": "LOW"
                },
                {
                    "id": "M20766",
                    "name": "Anesthetics, Intravenous",
                    "relevance": "LOW"
                },
                {
                    "id": "M20761",
                    "name": "Anesthetics, General",
                    "relevance": "LOW"
                },
                {
                    "id": "M20771",
                    "name": "Excitatory Amino Acid Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M20504",
                    "name": "Neurotransmitter Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Analg",
                    "name": "Analgesics"
                },
                {
                    "abbrev": "CNSDep",
                    "name": "Central Nervous System Depressants"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "PhSol",
                    "name": "Pharmaceutical Solutions"
                }
            ]
        }
    },
    "hasResults": false
}